Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
US Department of Justice

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,912,226

« Back to Dashboard

Summary for Patent: 5,912,226

Title: Anhydro- and isomer-A-21978C cyclic peptides
Abstract:Two new groups of A-21978C cyclic peptides, anhydro- and isomer-A21978C peptide derivatives, have antibacterial activity and are useful as intermediates. The two groups are prepared via transpeptidation of the parent cyclic peptides. Pharmaceutical formulations containing the new peptides as active ingredients and methods of treating infections caused by susceptible Gram-positive bacteria with the formulations are also provided. The invention also provides an antibacterial composition containing the new drug substance LY 146032 in substantially pure form.
Inventor(s): Baker; Patrick J. (Greenwood, IN), Debono; Manuel (Indianapolis, IN), Farid; Khadiga Z. (Lebanon, IN), Molloy; R. Michael (Danville, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:07/809,039
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

No matches for this query

International Patent Family for Patent: 5,912,226

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
HungaryT47154► Subscribe
European Patent Office0294990► Subscribe
Canada1315229► Subscribe
Bulgaria47349► Subscribe
Hungary201120► Subscribe
Australia1749388► Subscribe
Australia613640► Subscribe
Israel86601► Subscribe
JapanS6447388► Subscribe
New Zealand224873► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Queensland Health
Chinese Patent Office
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: